Medpace is still delivering strong revenue, margin, and cash flow growth, but softer bookings and a rich valuation keep the stock in Hold territory. The business quality is high, yet the current setup looks better on pullbacks than at full price.
Medpace Holdings Inc (MEDP) is a high-quality clinical research organization with a strong medium-term setup, but the stock already reflects much of that quality. The bullish case rests on three hard facts. First, the business is still growing at a healthy clip: Q1 2026 revenue rose 26.5% to $706.6M and diluted EPS rose to $4.28 from $3.67. Second, profitability and cash generation remain unusually strong for a services business, with a 20.0% Q1 operating margin, 21.1% Q1 EBITDA margin, $713.2M in 2025 operating cash flow, and $744.6M in trailing free cash flow. Third, the balance sheet is clean, with $497.0M of cash and equivalents at year-end 2025 against $250.5M of total debt, and Q1 cash climbed further to $652.7M.
The caution is just as real. Q1 2026 net book-to-bill was 0.88x, backlog growth was only 2.9% to $2.929B, and CEO August Troendle said cancellations reached their highest point in over a year. He also said gross awards were on the low end and acknowledged that the company needs either cancellations to abate or a bigger pipeline to support the growth rate it wants. That is the core tension in MEDP today: a very good business, but one facing softer booking conversion and a stock that still trades at 33.2x trailing earnings and 31.3x forward earnings.
For a balanced, moderate-risk investor with a medium-term horizon, MEDP looks more like a disciplined Buy on pullbacks than a stock to chase aggressively. The company has the operating quality, therapeutic depth, and financial strength to keep compounding, but the valuation leaves less room for execution stumbles while bookings and cancellations remain under a brighter spotlight.
Medpace is a full-service, science-led contract research organization that supports Phase I through Phase IV clinical development for pharmaceutical, biotechnology, and medical device customers. The company provides development plan design, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance, central laboratory services, imaging, bioanalytical lab work, clinical pharmacology, and post-marketing support. It operates globally across North America, Europe, Asia, South America, Africa, and Australia.
The company was founded in 1992, is headquartered in Cincinnati, Ohio, and trades on the Nasdaq under MEDP. It had about 6,300 employees, with Q1 2026 headcount at 6,320 versus 5,943 a year earlier. Medpace reports as one operating segment, which fits its integrated delivery model rather than a loose collection of business lines.
Scale has grown quickly. Revenue increased from $1.14B in 2021 to $2.53B in 2025. Net income rose from $181.8M to $451.1M over the same span. In Q1 2026, revenue reached $706.6M, EBITDA was $149.4M, and net income was $123.9M. That combination tells a simple story: Medpace is no longer a niche upstart. It is a scaled CRO with enough size to matter, but still focused enough to avoid becoming a sprawling bureaucracy.
Medpace does not report formal operating segments, but it does disclose revenue mix by therapeutic area. That mix matters because it shows where the company is strongest and where demand risk sits. For 2025, Oncology generated $747.6M or 29.5% of revenue, Metabolic generated $745.0M or 29.4%, Central Nervous System generated $254.8M or 10.1%, Cardiology generated $239.4M or 9.5%, Antiviral and Anti-Infective generated $134.9M or 5.3%, and Other generated $408.5M or 16.1%.
Oncology remains the anchor. It was 30.9% of 2024 revenue and 29.5% in 2025, so the mix stayed large and relatively stable. This is a favorable area for a CRO because oncology trials are complex, global, and data-heavy. The catch is that management also said oncology is a riskier field and has more cancellations. That means oncology is both a strength and a volatility source.
Metabolic has become equally important. Revenue in the category jumped from $457.5M in 2024 to $745.0M in 2025, lifting mix from 21.7% to 29.4%. In the Q1 2026 presentation, metabolic represented 23% of LTM/Q1 2026 mix versus 31% a year earlier, while oncology was 31% versus 29%. Management said metabolic has historically had the lowest cancellation rate among the therapeutic areas it breaks out, and described GLP-1-related work as a safe therapeutic area for the company. That matters because metabolic has been one of the clearest growth engines in the portfolio.
CNS and Cardiology are meaningful but secondary pillars. CNS rose from $182.0M in 2024 to $254.8M in 2025. Cardiology rose from $230.5M to $239.4M. Antiviral and Anti-Infective fell from $156.5M to $134.9M. Other declined modestly from $431.4M to $408.5M. The broad takeaway is that Medpace is not dependent on one narrow therapy bucket, but the business is increasingly driven by Oncology and Metabolic, which together represented nearly 59% of 2025 revenue.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Medpace is a services company, so there is no single flagship product in the way a device or software company would have one. The closest equivalent is its full-service clinical development platform, especially in Oncology and Metabolic programs where the company has built meaningful scale. That platform combines trial design, regulatory support, central lab capabilities, monitoring, data management, and operational execution under one roof.
The strongest flagship-like franchise inside that platform is probably Metabolic, particularly obesity-related work. August Troendle said the company had previously discussed that about 50% of its obesity work was directly related to GLP-1. He also said metabolic has the lowest historical cancellation rate and that GLP-1 work is "actually a pretty safe therapeutic area for us and things are very are going fine." Those comments matter because GLP-1 development has become one of the busiest lanes in biopharma, and Medpace already has a seat at that table.
The second flagship-like franchise is Oncology. It remains the largest therapeutic area by 2025 revenue at $747.6M. Oncology trials tend to be complex and sticky, which supports pricing and margin, but Troendle also said oncology is a riskier field and has more cancellations. That makes the franchise valuable, but not frictionless.
In plain English, Medpace’s flagship offering is not a molecule or machine. It is a repeatable operating model for difficult trials. That is less flashy than a product launch, but in CRO land, boring competence is often the real asset.
Medpace’s competitive edge starts with its integrated full-service model. The company says it competes on therapeutic expertise, staff quality, reliability, breadth of services, patient and investigator recruitment, global execution, speed, price, and overall value. Management has also made a strategic decision to avoid becoming a broad large-pharma outsourcing utility. Troendle said, "We've made a strategic decision not to play in large pharma," because that model would detract from Medpace’s focus on full-service internal expertise and efficient clinical development.
That choice gives MEDP a distinct lane. Rather than trying to be everything to everyone, the company has leaned into small and mid-sized biopharma and science-heavy programs where sponsors need more hands-on support. The 10-K says 79% of 2024 net revenue came from small biopharma and 17% from mid-sized biopharma. That customer set can be more volatile, but it also values execution and domain expertise more than sheer scale.
Therapeutic depth is another advantage. Medpace highlights strength in Oncology, Metabolic Disease, Cardiology, CNS, and Antiviral/Anti-Infective. Those are large and complicated areas where trial design and execution errors are expensive. A CRO that can reduce mistakes, speed enrollment, and manage regulators well becomes more than a vendor. It becomes part mechanic, part navigator.
AI is a future lever, but not a current margin catalyst. Troendle said AI will require meaningful investment and that over the next two years Medpace expects to spend more to pursue future benefits than it gains in efficiency. That is a sober answer in a market that often treats AI like a magic wand. It also makes the company’s commentary more credible.
The final advantage is reputation and execution discipline. Medpace beat EPS estimates in 7 straight reported quarters through Q1 2026, including an 8.1% surprise in April 2026 and an 11.7% surprise in February 2026. Consistent beats do not prove a moat by themselves, but they often signal a management team that understands its machine.
For Medpace, operations matter more than physical supply chain in the classic manufacturing sense. The key inputs are skilled labor, site relationships, regulatory know-how, and the ability to move studies through a global network without losing time or quality. That is why headcount, backlog conversion, cash collection, and hiring trends are more useful than inventory metrics.
On that front, Q1 2026 was solid. Backlog conversion was 23.3% of beginning backlog versus 19.2% a year earlier. Cash flow from operations was $151.8M. Net DSO was negative 58.8 days. The company ended the quarter with $652.7M in cash. Those are strong operating signals. A negative DSO profile, in particular, points to favorable working capital dynamics.
The pressure point is bookings quality. Net new business awards rose 23.7% to $618.4M in Q1 2026, but net book-to-bill was only 0.88x. Troendle said cancellations rose again and backlog cancels reached their highest point in over a year. He also said gross awards were on the low end, so the weaker book-to-bill was not just a cancellation story. It was a two-engine issue: more drag from cancels and less thrust from gross awards.
Management is still hiring, and Troendle framed that as a confidence signal. Q1 2026 headcount rose 6.3% YoY to 6,320. That supports the idea that Medpace still sees enough demand to invest in capacity. But investors should not ignore the mismatch between strong current revenue and weaker booking conversion. In a CRO, revenue is the wake. Bookings are the engine.
The broader outsourced clinical development market remains attractive. McKinsey said CRO and CDMO spending grew 12% to 13% annually from 2014 to 2022, faster than overall pharma R&D spending at 7% to 8%. McKinsey also said more than 80% of surveyed pharma R&D and supplier leaders expect supplier spending to increase 10% to 30% over the next two to five years. That is a favorable structural backdrop for CROs.
More directly, Grand View Research estimates the pharmaceutical CRO market at $48.47B in 2026, growing to $83.31B by 2033 at an 8.04% CAGR. Clinical trials support services are estimated at $27.54B in 2026, growing to $47.00B by 2033 at a 7.93% CAGR. Those figures support a medium-term view that outsourced development demand is still expanding, even if quarter-to-quarter bookings can wobble.
Medpace is positioned in attractive therapeutic areas. In 2025, Oncology and Metabolic together represented nearly 59% of revenue. The company also has meaningful exposure to CNS and Cardiology. Those are not sleepy backwaters. They are active development markets where sponsors need specialized trial execution.
The market opportunity is large enough to support continued share gains, but not every dollar of industry growth flows evenly. Medpace’s niche is high-touch, full-service work for smaller and mid-sized sponsors. That can be a better-margin lane than commodity outsourcing, but it also ties the company more closely to biotech funding conditions, reprioritizations, and program cancellations.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Medpace’s customer base is diversified by sponsor type, but it has a clear tilt toward smaller and mid-sized biopharma. The 10-K says 79% of 2024 net revenue came from small biopharma and 17% from mid-sized biopharma. That mix helps explain why Medpace emphasizes scientific partnership and full-service execution rather than broad enterprise outsourcing.
The Q1 2026 presentation showed customer tier mix of 63% Large Pharma, 28% Mid-sized Biopharma, and 9% Small Biopharma, versus 79%, 16%, and 5% respectively in Q1 2025. That shift points to a more balanced customer mix over the last year. It also suggests Medpace is broadening its revenue base even while management says it is not trying to become a large-pharma utility provider.
Customer concentration is manageable but worth watching. CFO Kevin Brady said the top 5 and top 10 customers represented roughly 28% and 37% of last 12 months revenue, respectively. That is not extreme concentration, but it is enough that program delays, M&A, or reprioritizations at a handful of sponsors can move results.
Management was blunt about one customer risk: biotech M&A is not good for Medpace. Troendle said when clients are acquired, Medpace is generally cut out of future work, though ongoing work often continues. That is one of the trade-offs of serving innovative smaller sponsors. You get growth and intimacy, but you also inherit their strategic turbulence.
Medpace names IQVIA, ICON, PPD within Thermo Fisher, and Fortrea as major CRO competitors, along with specialty and regional CROs and in-house sponsor teams. The company competes in a fragmented market where scale matters, but execution quality and therapeutic expertise can matter more.
Relative to larger peers, Medpace looks more focused than broad. It is not trying to match the widest data, technology, or commercial platform breadth of IQVIA or Thermo Fisher. Its stated edge is a disciplined operating model, full-service Phase I through IV capabilities, and therapeutic specialization. That narrower identity can be a strength because it keeps the company from drifting into lower-return complexity.
The downside of that focus is that Medpace has less diversification than the biggest peers. If cancellations rise in its key therapeutic areas or smaller sponsors pull back, MEDP has fewer unrelated business lines to cushion the hit. In other words, focus sharpens the blade, but it also means there is less padding around the edge.
Peer valuation data was not provided in the dataset, so the cleanest competitive conclusion comes from business quality rather than exact multiple spreads. Medpace’s 20.0% operating margin, 17.2% net margin, 77.3% ROE, and 17.5% ROA indicate a company operating at a high level inside the CRO group. That helps explain why the market has historically awarded it a premium multiple.
Medpace operates in a business that is shaped by biotech funding, pharma R&D budgets, regulatory complexity, foreign exchange, and cross-border trial execution. The 10-K notes exposure to foreign currency exchange rates, inflation, interest rates, and credit risk. Those are not abstract risks for a company running global studies across 46 countries.
The macro backdrop is mixed. On the positive side, outsourcing remains a structural tailwind, and the CRO market is still growing. On the negative side, Medpace’s customer base includes smaller biopharma sponsors that are more exposed to capital market conditions and portfolio reprioritization. Troendle said Q1 cancellations were not driven by acute financial shortages, but he also said the company has faced elevated cancellations over the last 18 months. That is a reminder that even when funding is not the direct culprit, sponsor behavior can still turn choppy.
Tax policy is another background factor. The 10-K discussed OECD Pillar Two developments and said the company does not anticipate a material impact on its tax provision or effective tax rate, but continues to monitor evolving legislation. For now, that looks like a watch item rather than a thesis breaker.
Geopolitically, a global CRO always carries execution risk across jurisdictions, sites, and regulators. Medpace’s multinational footprint is a competitive asset, but it also means the company must keep many moving parts aligned. In this business, friction rarely arrives with a trumpet. It usually shows up as slower starts, delayed milestones, or canceled studies.
$652.7M in cash and equivalents versus $250.5M of total debt leaves Medpace with a clean balance sheet and ample flexibility.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q1 2026 revenue jumped 26.5% to $706.6M while operating margin held at 20.0%, showing that growth is still translating into strong profitability.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Net book-to-bill fell to 0.88x and backlog growth slowed to 2.9% as cancellations hit their highest level in over a year.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →MEDP still trades at 33.2x trailing earnings and 31.3x forward earnings, leaving little room for execution misses.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →With a fair value of $460, the stock sits between the report’s Buy level at $400 and Sell level at $520.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Medpace is the kind of company investors usually want to own: focused, profitable, cash generative, and financially strong. Q1 2026 showed that the machine still works. Revenue grew 26.5%, EPS reached $4.28, EBITDA margin held at 21.1%, and cash climbed to $652.7M. Those are not the numbers of a business losing its footing.
But the market does not pay for yesterday’s quality alone. It pays for tomorrow’s confidence. Right now, that confidence is being tested by a 0.88x book-to-bill, backlog growth of just 2.9%, and management commentary that cancellations remain elevated and gross awards were on the low end. Those are not fatal issues, but they are real ones.
That leaves MEDP in a familiar but tricky category: a great company that is not automatically a great stock at any price. For moderate-risk investors with a medium-term horizon, the sensible stance is patience. The fair value estimate is $460, and the best opportunities will come when the market offers this operator at a price that leaves room for both its strengths and its frictions.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Medpace Holdings, Inc. (MEDP) jumps after-hours after posting a strong Q2 2026 earnings beat, higher revenue, and improved bookings. The CRO also raised full-year revenue guidance, signaling healthy demand and reinforcing its premium growth profile.
Medpace Holdings, Inc. (MEDP) slumps after hours despite a strong first quarter, as investors focus on weaker bookings and a sub-1.0x book-to-bill ratio. The company beat on revenue and earnings, but concerns about future demand and backlog growth drove the sharp selloff.
Medpace is delivering fast revenue growth, strong backlog, and net cash, but the stock already prices in a lot of good news. The report leans constructive, with a selective Buy on pullbacks rather than an aggressive chase.